Nuvation Bio (Nuvation Bio) Common Stock : $947.75 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Nuvation Bio Common Stock?

Nuvation Bio's quarterly common stock increased from Jun. 2023 ($938.40 Mil) to Sep. 2023 ($943.90 Mil) and increased from Sep. 2023 ($943.90 Mil) to Dec. 2023 ($947.75 Mil).

Nuvation Bio's annual common stock increased from Dec. 2021 ($909.99 Mil) to Dec. 2022 ($927.60 Mil) and increased from Dec. 2022 ($927.60 Mil) to Dec. 2023 ($947.75 Mil).

Nuvation Bio Common Stock Historical Data

The historical data trend for Nuvation Bio's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuvation Bio Common Stock Chart

Nuvation Bio Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Common Stock

289.48

909.99

927.60

947.75

Nuvation Bio Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Common Stock	Get a 7-Day Free Trial											927.60	932.74	938.40	943.90	947.75

Nuvation Bio Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Nuvation Bio (Nuvation Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuvation Bio Inc (NYSE:NUVB.WS) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

NUVB:USA

Address

1500 Broadway, Suite 1401, New York, NY, USA, 10036

Website

https://www.nuvationbio.com

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).